Cohance Lifesciences Ltd

- The transcript does not mention any current or planned fundraising activities through debt or equity. - There is no disclosure of upcoming capital raising events or financing plans. - The company highlights ongoing investments in quality systems, technology platforms, and capacity upgrades, funded through existing cash flows. - Free cash flow generation (INR175 crore in nine months FY26) and a sound balance sheet are noted, indicating internal funding of growth initiatives. - Management emphasizes careful budgeting and risk assessment for FY27 without specifying external funding needs. - Overall, no immediate or future fundraising via debt or equity is indicated in the provided call transcript.

- Capital expenditure during the first nine months of FY26 amounted to INR161 crore. - Investments primarily directed towards advancing differentiated platforms such as ADC (Antibody Drug Conjugates) and oligonucleotides. - Strengthening quality and compliance systems is a key investment focus. - Selective capacity and capability upgrades aligned with customer programs undertaken. - Continuous investment in leadership, business development, quality, and technology platforms. - Investment to support a broader and more complex pipeline, especially in the API Plus segment. - Emphasis on enhancing technology-led CRDMO platform through quality systems, regulatory capabilities, and complex chemistry platforms. - Strengthening leadership depth with experienced leaders for clearer accountability and execution discipline. - Ongoing remediation activities and risk management efforts at Nacharam formulation facility, including transfers to alternate facilities.

- Management remains committed to the USD 1 billion sales target by FY '30, though timing may shift slightly due to current challenges. - FY '27 is expected to be a growth year, driven by recovery in API Plus segment and pipeline progression across API and formulation businesses. - Increased traction in RFQs, including late-stage and commercial ones, is expected to translate into new business starting FY '27 and growing progressively. - Pipeline of early-stage commercial assets is strong, supporting expected value creation over the next 10 years. - Specialty Chemicals business is anticipated to improve earnings in FY '27 as qualification programs mature. - Overall, FY '27 growth is expected from diversification, successful pipeline commercialization, and recovery from timing-related disruptions experienced in FY '26. - API segment, representing ~50% of total sales, is also expected to see growth in FY '27 based on current customer engagement and market intelligence.

- FY '27 is expected to be a year of growth, driven by successful pipeline progression and recovery in the API Plus segment (Page 8). - Management remains fully committed to achieving the USD 1 billion sales target by FY '30, though timing may shift due to current challenges (Page 9). - Near-term margin pressure is attributed to business mix, volume, and consolidation effects rather than a structural shift, with expectations to achieve 30%+ margins mid-term (Page 14-15). - Despite FY '26 pressures, the underlying platform and technology capabilities remain intact, positioning the business for recovery as customer drawdowns normalize and commercial assets scale (Page 9). - Free cash flow generation remains resilient, with INR175 crore generated in the first nine months of FY '26, supporting sound balance sheet and steady capital investments (Page 9). - Improved order books and increased late-stage RFPs indicate higher revenue visibility for FY '27 onwards (Page 7-8).

- The Pharma CDMO business has seen a meaningful increase in late-stage RFP activity from both new and existing customers, with a double-digit number of commercial and late-stage RFPs secured recently. - The business development team was completed in December, leading to strengthened prospects for FY '27. - The Q4 order book remains healthy and consistent with seasonally stronger demand profiles. - Pipeline across API and formulation is broader, showing significant improvement in inquiry flow. - RFQ conversion rate is around 20%, with much higher RFQ volumes for Phase 3 and commercial projects. - Orders from new customer engagements and existing programs are expected to start yielding business progressively through FY '27. - Business development is focused on new molecules, alternate sourcing, and wallet share expansion. - For the API Plus segment, despite delays and product-specific challenges, the order book indicates gradual recovery for FY '27.